Please assess the completion status of the following clinical trial:

Trial Title: Paracervical Injection for Headache in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 64 years~* Suspected diagnosis of benign or primary headache~Exclusion Criteria:~* Treating attending physician is suspicious of a serious secondary cause of headache~* History of brain disease, concussion, stroke, intracranial mass or tumor, hemorrhage, increased intracranial pressure, head trauma in last 2 weeks, status post intracranial surgery~* History of neck disease, cervical spine or disc abnormality, history of vertebral or carotid artery dissection, torticollis, status post cervical spine surgery or hardware in place~* Hypersensitivity or allergy to bupivacaine (amide anesthetics) or prochlorperazine (dopamine receptor antagonists)~* Overlying signs of infection at site of injection (erythema, purulence, open skin)~* History of extrapyramidal symptoms, dystonia, parkinsonism, tardive dyskinesia or neuroleptic malignant syndrome~* Pregnancy~* History of schizophrenia or bipolar disorder~* Narcotic seeking patients as determined by the treating attending physician with optional assistance from medical record and online database review~* Weight more than 150 kg or less than 40 kg~* Received pain medication in the ED or less than 6 hours prior to enrollment~* Temperature greater than 38 degrees Celcius~* Previous enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Paracervical injection (Type: EXPERIMENTAL): 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
- Standard treatment (Type: ACTIVE_COMPARATOR): Intravenous administration of prochlorperazine and diphenhydramine.

Based on this trial design, predict the completion outcome and termination type (if applicable).